Literature DB >> 12167664

Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.

Han C Dan1, Mei Sun, Lin Yang, Richard I Feldman, Xue-Mei Sui, Chien Chen Ou, Mark Nellist, Raymond S Yeung, Dicky J J Halley, Santo V Nicosia, Warren J Pledger, Jin Q Cheng.   

Abstract

Normal cellular functions of hamartin and tuberin, encoded by the TSC1 and TSC2 tumor suppressor genes, are closely related to their direct interactions. However, the regulation of the hamartin-tuberin complex in the context of the physiologic role as tumor suppressor genes has not been documented. Here we show that insulin or insulin growth factor (IGF) 1 stimulates phosphorylation of tuberin, which is inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the mitogen-activated protein kinase inhibitor PD98059. Expression of constitutively active PI3K or active Akt, including Akt1 and Akt2, induces tuberin phosphorylation. We further demonstrate that Akt/PKB associates with hamartin-tuberin complexes, promoting phosphorylation of tuberin and increased degradation of hamartin-tuberin complexes. The ability to form complexes, however, is not blocked. Akt also inhibits tuberin-mediated degradation of p27(kip1), thereby promoting CDK2 activity and cellular proliferation. Our results indicate that tuberin is a direct physiological substrate of Akt and that phosphorylation of tuberin by PI3K/Akt is a major mechanism controlling hamartin-tuberin function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167664     DOI: 10.1074/jbc.M205838200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  120 in total

1.  AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation.

Authors:  Wilfred Lieberthal; Leiqing Zhang; Vimal A Patel; Jerrold S Levine
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

Review 2.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes.

Authors:  Jianling Xie; Terence P Herbert
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

3.  Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.

Authors:  Yue Wu; Rishi Raj Chhipa; Jinrong Cheng; Haitao Zhang; James L Mohler; Clement Ip
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

Review 4.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 5.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

6.  IGF-I activates the eIF4F system in cardiac muscle in vivo.

Authors:  Thomas C Vary; Charles H Lang
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

7.  ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling.

Authors:  Jeremiah N Winter; Leonard S Jefferson; Scot R Kimball
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

8.  TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.

Authors:  Qian Yang; Ken Inoki; Eunjung Kim; Kun-Liang Guan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-20       Impact factor: 11.205

9.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

Review 10.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.